Determination of Sustained Virological Response in Hepatitis C Virus Genotypes by the Number of Mutations in the E2 and NS5A-ISDR Regions: A Meta-Analysis


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

Since last few decades hepatitis C virus (HCV) has been a major cause of death due to the involvement of acute and chronic type of liver diseases throughout the world. Genotype variability and mutations occurring at different regions of HCV genome provides a critical parameter for the study of sustained virological response (SVR) against mono and combinational therapies. Most of these mutations occurring in E2 and NS5A-ISDR regions in HCV genotypes play a significant role in SVR against Interferon-monotherapy and combination therapy. Therefore, the aim of the present study is to evaluate the SVR in various genotypes and the role of mutations in specific regions. In line with this, the NS5A and E2 proteins of HCV genotype 1 were found to suppress the double-stranded (ds) RNA-dependent protein kinase (PKR), which in turn is entailed in the cellular antiviral response stimulated by interferon (IFN). The response to IFN therapy varies between genotypes, with response rates among patients infected with types 2 and 3 nearly two-three-fold greater than in patients infected with type 1. Surprisingly, a considerable percentage of HCV genotype 3a infected patients do not react to treatment at all. In Japan, a link was observed between the numbers of mutations in an “interferon sensitivity determining region” (ISDR) and the result of interferon treatment in genotype 1b infected patients. Therefore, we published data on E2 (PePHD) and NS5A-ISDR regions including our data on SVR of different HCV genotypes, the relationship between the number and patterns of mutations in the E2 (PePHD) and NS5A-ISDR regions and responsiveness to IFN therapy.

Об авторах

S. Rahamathulla

PathGene Healthcare Private Limited

Автор, ответственный за переписку.
Email: syedrahamathullabio@gmail.com
Индия, Tirupati, Andhra Pradesh, 517501

B. Ratnagiri

Gastroenterologist, Hepatologist and Therapeutic Endoscopist

Email: syedrahamathullabio@gmail.com
Индия, Vijayawada, Andhra Pradesh, 520001

M. Manickam

PathGene Healthcare Private Limited

Email: syedrahamathullabio@gmail.com
Индия, Tirupati, Andhra Pradesh, 517501

S. Sultana

Department of Sericulture

Email: syedrahamathullabio@gmail.com
Индия, Tirupathi, Andhra Pradesh, 517502

D. Mamatha

Department of Sericulture

Email: syedrahamathullabio@gmail.com
Индия, Tirupathi, Andhra Pradesh, 517502

O. Magisetty

PathGene Healthcare Private Limited

Email: syedrahamathullabio@gmail.com
Индия, Tirupati, Andhra Pradesh, 517501

R. Nagarapu

Center for Liver Research and Diagnostics

Email: syedrahamathullabio@gmail.com
Индия, Hyderabad, Telangana, 500058

S. Ponamgi

Jawaharlal Nehru Technological University Hyderabad, Kukatpally

Email: syedrahamathullabio@gmail.com
Индия, Hyderabad, Telangana, 500085

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML

© Pleiades Publishing, Inc., 2018

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).